DUPIXENT is not an immunosuppressant and avoids broad immunosuppression. It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with preexisting helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves. DUPIXENT is a human monoclonal antibody that inhibits the signaling of IL-4 and IL-13, two of the key cytokines that contribute to type 2 inflammation in asthma. The mechanism of dupilumab action has not been definitively established.1

In the DUPIXENT pivotal clinical trials, the most common adverse reactions (incidence ≥1%) in patients with asthma were injection site reactions, oropharyngeal pain, and eosinophilia. The safety profile of DUPIXENT in children 6-11 years of age with moderate-to-severe asthma through Week 52 was similar to the safety profile from studies in adult and pediatric subjects 12 years of age and older with moderate-to-severe asthma with the addition of helminth infections. Helminth infections were reported in 2.2% (6 subjects) in the DUPIXENT group and 0.7% (1 subject) in the placebo group. The majority of cases were enterobiasis, reported in 1.8% (5 subjects) in the DUPIXENT group and none in the placebo group. There was 1 case of ascariasis in the DUPIXENT group. All helminth infection cases were mild to moderate, and subjects recovered with anti-helminth treatment without DUPIXENT treatment discontinuation.1